Skip to main navigation
Cue Logo
Skip to Content
Cue Logo
  • Overview
  • News & Events
    • News Releases
    • Events and Presentations
  • Corporate Governance
    • Governance Overview
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Quarterly Results
  • Stock Information
    • Stock Quote
    • Analyst Coverage
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact Investor Relations

SEC
Filing Details

Document Details

Form
4
Filing Date
Sep 8, 2022
Document Date
Sep 6, 2022
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Cue Health Inc.
Issuer
CUE HEALTH INC.
Filer
Gallagher John E

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Shareholder Tools

Print Page Print Page
Email Alerts Email Alerts
RSS RSS
Contact Contact

This website contains depictions of contemplated future products and future care offerings that are still under development by Cue Health and that have not received regulatory authorization, clearance or approval. Currently, Cue Health's products authorized for commercial sale in the United States are the Cue COVID-19 Test Kit and the Cue Mpox Molecular Test Kit, both authorized under Emergency Use Authorization from the U.S. Food & Drug Administration (the “FDA”) and the COVID-19 Molecular Test Kit (De Novo granted by the FDA).

  • © 2024 Cue Health Inc. All rights reserved. Cue and the Cue logo are registered trademarks of Cue Health Inc.